Volume | 170,069 |
|
|||||
News | - | ||||||
Day High | 201.00 | Low High |
|||||
Day Low | 191.20 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Madrigal Pharmaceuticals Inc | MDGL | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
200.63 | 191.20 | 201.00 | 204.65 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,852 | 170,069 | $ 195.30 | $ 33,215,306 | - | 119.7604 - 322.67 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
10:48:57 | 100 | $ 192.2075 | USD |
Madrigal Pharmaceuticals (MDGL) Options Flow Summary
Madrigal Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
3.84B | 19.90M | - | 0 | -373.63M | -18.78 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Madrigal Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MDGL Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 227.78 | 227.90 | 190.73 | 212.86 | 521,161 | -35.57 | -15.62% |
1 Month | 258.54 | 268.22 | 190.73 | 233.79 | 391,865 | -66.33 | -25.66% |
3 Months | 218.87 | 298.00 | 168.2462 | 235.13 | 604,963 | -26.66 | -12.18% |
6 Months | 124.15 | 298.00 | 119.7604 | 219.41 | 479,210 | 68.06 | 54.82% |
1 Year | 305.83 | 322.67 | 119.7604 | 213.30 | 428,244 | -113.62 | -37.15% |
3 Years | 130.28 | 322.67 | 52.33 | 178.33 | 316,158 | 61.93 | 47.53% |
5 Years | 106.12 | 322.67 | 52.33 | 158.00 | 256,111 | 86.09 | 81.12% |
Madrigal Pharmaceuticals Description
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action. |